45 related articles for article (PubMed ID: 3157344)
1. Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis.
Sullam PM; Täuber MG; Hackbarth CJ; Sande MA
Antimicrob Agents Chemother; 1985 Jan; 27(1):135-6. PubMed ID: 3157344
[TBL] [Abstract][Full Text] [Related]
2. Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.
Garcia-de-la-Maria C; Xiong YQ; Pericas JM; Armero Y; Moreno A; Mishra NN; Rybak MJ; Tran TT; Arias CA; Sullam PM; Bayer AS; Miro JM
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264848
[TBL] [Abstract][Full Text] [Related]
3. Enterococcus spp. and Streptococcus spp. bloodstream infections: epidemiology and therapeutic approach.
Blanes Hernández R; Blanes Juliá M
Rev Esp Quimioter; 2023 Nov; 36 Suppl 1(Suppl 1):2-4. PubMed ID: 37997861
[TBL] [Abstract][Full Text] [Related]
4. Dalbavancin as a treatment option for Rothia aeria endocarditis.
Toledo H; Gimeno A; Alarcón JC; Luque-Márquez R
Rev Esp Quimioter; 2024 Feb; 37(1):100-101. PubMed ID: 38131630
[No Abstract] [Full Text] [Related]
5. Treatment of
Herrera-Hidalgo L; Fernández-Rubio B; Luque-Márquez R; López-Cortés LE; Gil-Navarro MV; de Alarcón A
Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107066
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of teicoplanin monotherapy following initial standard therapy in Enterococcus faecalis infective endocarditis: a retrospective cohort study.
De Nadaï T; François M; Sommet A; Dubois D; Metsu D; Grare M; Marchou B; Delobel P; Martin-Blondel G
Infection; 2019 Jun; 47(3):463-469. PubMed ID: 30809761
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of daptomycin and teicoplanin against enterococci isolated from blood and urine.
Forward KR; Degagne P; Bartlett KR; Harding GK
Can J Infect Dis; 1992 Jul; 3(4):173-8. PubMed ID: 22514366
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis.
López P; Gavaldà J; Martin MT; Almirante B; Gomis X; Azuaje C; Borrell N; Pou L; Falcó V; Pigrau C; Pahissa A
Antimicrob Agents Chemother; 2001 May; 45(5):1387-93. PubMed ID: 11302800
[TBL] [Abstract][Full Text] [Related]
9. Current perspectives on glycopeptide resistance.
Woodford N; Johnson AP; Morrison D; Speller DC
Clin Microbiol Rev; 1995 Oct; 8(4):585-615. PubMed ID: 8665471
[TBL] [Abstract][Full Text] [Related]
10. Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections.
Galanakis N; Giamarellou H; Vlachogiannis N; Dendrinos C; Daikos GK
Eur J Clin Microbiol Infect Dis; 1988 Apr; 7(2):130-4. PubMed ID: 2968907
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment.
Domart Y; Pierre C; Clair B; Garaud JJ; Regnier B; Gibert C
Antimicrob Agents Chemother; 1987 Oct; 31(10):1600-4. PubMed ID: 2963586
[TBL] [Abstract][Full Text] [Related]
12. The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis.
Webster A; Wilson AP; Williams AH; Treasure T; Grüneberg RN
Postgrad Med J; 1987 Aug; 63(742):621-4. PubMed ID: 2962071
[TBL] [Abstract][Full Text] [Related]
13. Teicoplanin in the treatment of gram-positive-bacterial endocarditis.
Martino P; Venditti M; Micozzi A; Brandimarte C; Gentile G; Santini C; Serra P
Antimicrob Agents Chemother; 1989 Aug; 33(8):1329-34. PubMed ID: 2529815
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients.
Leport C; Perronne C; Massip P; Canton P; Leclercq P; Bernard E; Lutun P; Garaud JJ; Vilde JL
Antimicrob Agents Chemother; 1989 Jun; 33(6):871-6. PubMed ID: 2527483
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology of enterococci.
Chenoweth C; Schaberg D
Eur J Clin Microbiol Infect Dis; 1990 Feb; 9(2):80-9. PubMed ID: 2180711
[TBL] [Abstract][Full Text] [Related]
16. Therapy of enterococcal infections.
Eliopoulos GM; Eliopoulos CT
Eur J Clin Microbiol Infect Dis; 1990 Feb; 9(2):118-26. PubMed ID: 2180707
[TBL] [Abstract][Full Text] [Related]
17. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
Campoli-Richards DM; Brogden RN; Faulds D
Drugs; 1990 Sep; 40(3):449-86. PubMed ID: 2146108
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.
Yao JD; Thauvin-Eliopoulos C; Eliopoulos GM; Moellering RC
Antimicrob Agents Chemother; 1990 May; 34(5):827-30. PubMed ID: 2141778
[TBL] [Abstract][Full Text] [Related]
19. Screening and treatment of infections caused by resistant enterococci.
Herman DJ; Gerding DN
Antimicrob Agents Chemother; 1991 Feb; 35(2):215-9. PubMed ID: 2024952
[No Abstract] [Full Text] [Related]
20. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis.
Rybak MJ; Lerner SA; Levine DP; Albrecht LM; McNeil PL; Thompson GA; Kenny MT; Yuh L
Antimicrob Agents Chemother; 1991 Apr; 35(4):696-700. PubMed ID: 1829880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
